Xenon

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Tuesday, April 16, 2024
Xenon, American Academy, Efficacy, Safety, Abstract, AAN, Epilepsy, Extension, Annual general meeting

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.

Key Points: 
  • VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.
    Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension study and an overview of the impact of disease severity on responder rates in the X-TOLE Phase 2b study, were selected as oral presentations at this year’s annual meeting of the American Academy of Neurology.
  • We are grateful to our epilepsy key opinion leaders Dr. Jacqueline French and Dr. Roger Porter for presenting the XEN1101 data.
  • This is an important opportunity for us to connect with leading neurologists to highlight our late-stage clinical work in both epilepsy and major depressive disorder.”
    Oral Presentation #005 (French et al.)
  • “Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy.”
    Oral Presentation #004 (Porter et al.)

Arc-based Plasma Lighting Market worth $676 million by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 15, 2024
Xenon, Edison light bulb, Mercury-vapor lamp, PV, ABA, Hospital, Manufacturing execution system, LEDVANCE, Statistics, Photography, Commercial, Ams-OSRAM, Analog, Class, UV curing, Light meter, Dimension, High, Light, Digital, Ultraviolet, LED, Electronics, Medicine, Metal, Newport Corporation, ABB, Plasma, UV, Row

This segment caters to applications necessitating exceptionally high-intensity lighting, such as large outdoor venues, sports stadiums, and industrial facilities.

Key Points: 
  • This segment caters to applications necessitating exceptionally high-intensity lighting, such as large outdoor venues, sports stadiums, and industrial facilities.
  • These sectors require powerful lighting solutions to ensure adequate illumination over expansive areas, thereby driving the demand for high-wattage plasma lighting systems.
  • Asia Pacific is estimated to account for the largest market share in the global arc-based plasma lighting industry by 2029.
  • (Japan), LEDVANCE GmbH (Germany), and Newport Corporation (US) are some of the major companies in the arc-based plasma lighting companies .

Arc-based Plasma Lighting Market worth $676 million by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 15, 2024
Xenon, Edison light bulb, Mercury-vapor lamp, PV, ABA, Hospital, Manufacturing execution system, LEDVANCE, Statistics, Photography, Commercial, Ams-OSRAM, Analog, Class, UV curing, Light meter, Dimension, High, Light, Digital, Ultraviolet, LED, Electronics, Medicine, Metal, Newport Corporation, ABB, Plasma, UV, Row

This segment caters to applications necessitating exceptionally high-intensity lighting, such as large outdoor venues, sports stadiums, and industrial facilities.

Key Points: 
  • This segment caters to applications necessitating exceptionally high-intensity lighting, such as large outdoor venues, sports stadiums, and industrial facilities.
  • These sectors require powerful lighting solutions to ensure adequate illumination over expansive areas, thereby driving the demand for high-wattage plasma lighting systems.
  • Asia Pacific is estimated to account for the largest market share in the global arc-based plasma lighting industry by 2029.
  • (Japan), LEDVANCE GmbH (Germany), and Newport Corporation (US) are some of the major companies in the arc-based plasma lighting companies .

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Tuesday, March 5, 2024
Xenon, Conference

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.

Key Points: 
  • VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.
  • Company Fireside Chat Presentation Details:

Japanese Studio 'Cocone' Launches AlterEgo City on iOS and Android

Retrieved on: 
Thursday, March 7, 2024
Xenon, Friends, IOS, App Store (iOS/iPadOS), Google Play, Social, Music, Android, Centennial, AlterEgo, Video game

NEW YORK, March 7, 2024 /PRNewswire/ -- Cocone, a leading Japanese immersive entertainment studio at the forefront of avatar and digital fashion creation, today announced the launch of AlterEgo City (formerly known as Centennial and AlterEgo City), a unique digital experience at the intersection of art, fashion, and music, now available on iOS and Android devices via the Apple App Store and Google Play. The launch of AlterEgo City represents the first major games release from Cocone in the US market, and stands as a testament to the company's work in digital avatar creation.

Key Points: 
  • The launch of AlterEgo City represents the first major games release from Cocone in the US market, and stands as a testament to the company's work in digital avatar creation.
  • AlterEgo City transports players to the visually stunning and bustling world of Centennial, an immersive experience that offers them the chance to customize and design their own unique digital avatar.
  • AlterEgo City also offers players the chance to produce their own music, with the ability to develop custom tracks that can be heard through the player's AlterEgo.
  • For more information about AlterEgo City, including how to download the game for iOS and Android devices, please visit https://www.alter-ego.city/

JCB partners with FrenchSys to boost card acceptance across France

Retrieved on: 
Tuesday, November 28, 2023
JCB Co., Ltd., Partnership, PIN, Certification, News, Level 3, JCB, CBI, Growth, Xenon, Online shopping

Tokyo, London, Paris, Nov 28, 2023 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd. (JCB), announced its partnership with FrenchSys, a subsidiary of CB-Investissements (CBI), to facilitate a greater JCB certification process for payment terminals across France.

Key Points: 
  • Tokyo, London, Paris, Nov 28, 2023 - (JCN Newswire) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd. (JCB), announced its partnership with FrenchSys, a subsidiary of CB-Investissements (CBI), to facilitate a greater JCB certification process for payment terminals across France.
  • This alliance helps banks, terminal manufacturers, and merchant partners to accept JCB Cards through an integrated certification process, hosted by FrenchSys.
  • This development will allow our valuable cardmembers to use their JCB Cards more widely throughout France, which is fantastic news for them and the merchant partners who serve them.
  • Cedric Sarazin, Managing Director, FrenchSys, added: "FrenchSys was established in 2019 to facilitate the acceptance of multi-scheme payments in France, serving acquirers, card schemes, manufacturers, and digital payment processors.

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, December 4, 2023
Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Equity capital markets, Exercise, Security (finance)

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.
  • The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $345.0 million.
  • J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets acted as joint book-running managers for the offering.
  • The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

Retrieved on: 
Saturday, December 2, 2023
Xenon, Quality of life, Skill, SCN1A, Convention, Aes, Efficacy, Depression, Epilepsy, AES, Poster, American Epilepsy Society, ASMS, DSM-IV codes, SFG, Seizure, MPC, Dravet syndrome, Anxiety, Annual general meeting, Neurology, Food, Safety, MDD, Patient, Orange County Convention Center, OLE, Pharmaceutical industry

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).
  • Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial.
  • The exhibit will also feature the topline results from the Phase 2 proof-of-concept X-NOVA clinical trial in major depressive disorder.
  • Posters will be added to the Xenon website consistent with AES 2023 conference guidelines.

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

Retrieved on: 
Thursday, November 30, 2023
Xenon, Telephone, Suite, Montgomery Street, Sale, Jefferies Group, Attention, Jefferies, RBC Capital Markets, BofA Securities, Vesey Street, Prospectus, Madison Avenue, Broadridge Financial Solutions, Equity capital markets, Security (finance)

The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.

Key Points: 
  • The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $300.0 million.
  • In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,384,615 common shares at the public offering price, less the underwriting discounts and commissions.
  • J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.
  • These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering.